BridgeBio Pharma, Inc.
BBIO
$32.19
-$0.82-2.48%
| Weiss Ratings | BBIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | BBIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Fair | |||
| Total Return Index | Fair | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | BBIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.94 | |||
| Price History | BBIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 1.96% | |||
| 30-Day Total Return | 3.74% | |||
| 60-Day Total Return | 15.71% | |||
| 90-Day Total Return | 27.74% | |||
| Year to Date Total Return | 14.15% | |||
| 1-Year Total Return | 15.75% | |||
| 2-Year Total Return | 129.93% | |||
| 3-Year Total Return | 188.96% | |||
| 5-Year Total Return | 99.81% | |||
| 52-Week High % Change | -16.37% | |||
| 52-Week Low % Change | 52.68% | |||
| Price | BBIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $39.47 | |||
| 52-Week Low Price | $21.62 | |||
| 52-Week Low Price (Date) | Jun 24, 2024 | |||
| 52-Week High Price (Date) | Feb 20, 2025 | |||
| Valuation | BBIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 6.28B | |||
| Enterprise Value | 7.34B | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -2.85 | |||
| Earnings Per Share Growth | -27.90% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 28.18 | |||
| Price/Book (Q) | -4.27 | |||
| Enterprise Value/Revenue (TTM) | 33.07 | |||
| Price | $32.19 | |||
| Enterprise Value/EBITDA (TTM) | -12.84 | |||
| Enterprise Value/EBIT | -12.71 | |||
| Market Cap Category | Mid Cap | |||
| Dividends and Shares | BBIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 189.44M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | BBIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 650 391 9740 | |||
| Address | 3160 Porter Drive Palo Alto, CA 94304 | |||
| Website | bridgebio.com | |||
| Country | United States | |||
| Year Founded | 2015 | |||
| Profitability | BBIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -260.19% | |||
| Profit Margin | -241.44% | |||
| Management Effectiveness | BBIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -49.24% | |||
| Return on Equity | -- | |||
| Income Statement | BBIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 221.90M | |||
| Total Revenue (TTM) | 221.90M | |||
| Revenue Per Share | $1.17 | |||
| Gross Profit (TTM) | 218.02M | |||
| EBITDA (TTM) | -571.29M | |||
| EBIT (TTM) | -577.37M | |||
| Net Income (TTM) | -535.76M | |||
| Net Income Avl. to Common (TTM) | -535.76M | |||
| Total Revenue Growth (Q YOY) | 237.08% | |||
| Earnings Growth (Q YOY) | -56.98% | |||
| EPS Diluted (TTM) | -2.85 | |||
| EPS Diluted Growth (Q YOY) | -45.16% | |||
| Balance Sheet | BBIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 681.10M | |||
| Cash Per Share (Q) | $3.60 | |||
| Total Current Assets (Q) | 720.69M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | -1.46B | |||
| Current Ratio (Q) | 4.668 | |||
| Book Value Per Share (Q) | -$7.72 | |||
| Total Assets (Q) | 919.34M | |||
| Total Current Liabilities (Q) | 154.40M | |||
| Total Debt (Q) | 1.73B | |||
| Total Liabilities (Q) | 2.38B | |||
| Total Common Equity (Q) | -1.47B | |||
| Cash Flow | BBIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 60.78M | |||
| Cash from Financing (TTM) | 748.46M | |||
| Net Change in Cash (TTM) | 288.51M | |||
| Levered Free Cash Flow (TTM) | -298.58M | |||
| Cash from Operations (TTM) | -520.73M | |||
